Assertio Therapeutics, Inc. (ASRT): Price and Financial Metrics

Assertio Therapeutics, Inc. (ASRT)

Today's Latest Price: $1.29 USD

0.05 (-3.73%)

Updated Feb 18 8:00pm

Add ASRT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ASRT Stock Summary

  • As for revenue growth, note that ASRT's revenue has grown -41.45% over the past 12 months; that beats the revenue growth of only 4.52% of US companies in our set.
  • In terms of volatility of its share price, ASRT is more volatile than 97.17% of stocks we're observing.
  • Assertio Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 171.67%, greater than the shareholder yield of 98.35% of stocks in our set.
  • Stocks that are quantitatively similar to ASRT, based on their financial statements, market capitalization, and price volatility, are CPHI, ROYL, SATS, LTHM, and CGIX.
  • Visit ASRT's SEC page to see the company's official filings. To visit the company's web site, go to
ASRT Daily Price Range
ASRT 52-Week Price Range

ASRT Stock Price Chart More Charts

ASRT Price/Volume Stats

Current price $1.29 52-week high $5.76
Prev. close $1.34 52-week low $0.68
Day low $1.22 Volume 1,206,900
Day high $1.35 Avg. volume 2,502,534
50-day MA $1.15 Dividend yield N/A
200-day MA $1.90 Market Cap 104.08M

Assertio Therapeutics, Inc. (ASRT) Company Bio

Assertio Therapeutics, Inc. (formerly DepoMed) develops products for pain and other central nervous system conditions in the United States. The company was founded in 1995 and is focused in Newark, California.

ASRT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for ASRT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Assertio Therapeutics Inc ranked in the 95st percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 4524%. The most interesting components of our discounted cash flow analysis for Assertio Therapeutics Inc ended up being:

  • 21% of the company's capital comes from equity, which is greater than just 5.94% of stocks in our cash flow based forecasting set.
  • Assertio Therapeutics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 0.13. This coverage rate is greater than that of merely 18.52% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, Assertio Therapeutics Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ASRT, try RDY, FVE, BEAT, USNU, and CORT.

ASRT Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ASRT Latest Social Stream

Loading social stream, please wait...

View Full ASRT Social Stream

ASRT Price Returns

1-mo N/A
3-mo 73.34%
6-mo -7.86%
1-year -71.21%
3-year N/A
5-year N/A
YTD 3.20%
2019 -65.37%
2018 -55.16%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7168 seconds.